Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies

Video content above is prompted by the following:

• Briefly review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation and discuss associated implications. (ESMO CLL Guideline Update 2024)
  • How does the presence of TP53 or del(17p) mutations alter your overall treatment approach?
  • How does the role of time-limited vs continuous BTKi therapy in the 1L setting differ in this patient population?
• Briefly comment on the underlying rationale and data supporting BTKi therapy as a preferred approach in this setting.
  • SEQUOIA – Shadman M, et al. ASH 2024. Abs 3249
  • ELEVATE-TN – Sharman JP, et al. ASH 2023. Abs 642